Oncotelic Therapeutics completes final tranche of private financing

Oncotelic Therapeutics ( (OTLC) ) has provided an update.

On December 31, 2025, Oncotelic Therapeutics, Inc. completed the third and final tranche of a private offering, issuing 44 units to 22 accredited investors under subscription agreements, while two prior investors holding a total of seven units from a 2023 private placement memorandum did not participate. Each unit in the offering consists of a $25,000 note bearing 12% annual interest maturing two years after the final closing, convertible into either 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share, along with associated warrants to purchase additional shares of either Oncotelic or EdgePoint at preset prices, all subject to anti-dilution protections. As part of the transaction, the company treated existing 2023 notes as paid off and rolled investor contributions into the new notes, extended the life of previously issued 2023 warrants by two years, and granted investors the option to convert EdgePoint shareholdings into Oncotelic stock at an exchange rate of 10 Oncotelic shares for each EdgePoint share, potentially aligning interests more directly with the parent company; it also entered into a registration rights agreement covering the common shares issued and issuable under the financing, signaling a move to enhance liquidity and investor protections for these securities. The securities were issued under an exemption from Securities Act registration requirements, reinforcing the company’s reliance on private capital markets to support its capital structure and strategic relationship with its AI-focused subsidiary.

The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.

Spark’s Take on OTLC Stock

According to Spark, TipRanks’ AI Analyst, OTLC is a Neutral.

The score is held down primarily by weak financial performance (minimal revenue, losses, ongoing cash burn) and elevated leverage for a pre-revenue biotech. Technical indicators also point to weak momentum. Corporate events provide some offset via improved financing flexibility and a platform launch, but valuation remains difficult to support due to negative earnings.

To see Spark’s full report on OTLC stock, click here.

More about Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. operates in the biotechnology and therapeutics sector, focusing on the development of oncology-related products and leveraging its consolidated minority-owned subsidiary EdgePoint AI, Inc. as part of its broader platform. The company uses structured financing instruments, including convertible notes and equity-linked securities, to fund its operations and advance its clinical and technological initiatives in the healthcare and AI-enabled biotech space.

Average Trading Volume: 254,912

Technical Sentiment Signal: Buy

Current Market Cap: $34.43M

Find detailed analytics on OTLC stock on TipRanks’ Stock Analysis page.